About Transvascular
Transvascular is a company based in Menlo Park (United States) founded in 1996 was acquired by Medtronic in August 2003. Transvascular has raised $10.8 million across 2 funding rounds from investors including Medtronic, Bessemer Venture Partners and NEA. Transvascular operates in a competitive market with competitors including Silk Road Medical, Lifetech Scientific Corporation, HDL Therapeutics, Supira Medical and S4 Medical, among others.
- Headquarter Menlo Park, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Transvascular
Transvascular has successfully raised a total of $10.8M across 2 strategic funding rounds. The most recent funding activity was a Series D round of $10.8 million completed in May 2002. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Transvascular
Transvascular has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include Medtronic, Bessemer Venture Partners and NEA.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital investments are offered to startups by NEA.
|
Locked | Locked | Locked | |
|
Venture capital firm backed by Johnson & Johnson
|
Locked | Locked | Locked | |
|
Life science & tech focused VC firm investing in companies in the US
|
Locked | Locked | Locked |
Investor details for Transvascular
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Transvascular
Investment portfolio details for Transvascular
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Transvascular
Detailed financials for Transvascular
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Transvascular Comparisons
Peer comparison for Transvascular
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Transvascular
Transvascular operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Silk Road Medical, Lifetech Scientific Corporation, HDL Therapeutics, Supira Medical and S4 Medical, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Provider of neuroprotection devices for carotid artery disease
|
|
| Locked | Locked | Locked |
Interventional devices for cardiovascular and vascular diseases are developed.
|
|
| Locked | Locked | Locked |
Therapy to reverse coronary atherosclerosis is developed using patient plasma.
|
|
| Locked | Locked | Locked |
Developer of ventricular assist devices for coronary intervention and cardiogenic shock
|
|
| Locked | Locked | Locked |
Catheter ablation treatments for atrial fibrillation are developed.
|
Detailed competitors of Transvascular
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Transvascular
Complete news archive for Transvascular
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Transvascular
Transvascular was founded in 1996.
Transvascular is headquartered in Menlo Park, United States. It is registered at Menlo Park, California, United States.
Transvascular is a funded company, having raised a total of $10.8M across 2 funding rounds to date.
Transvascular was founded in 1996 in Menlo Park, United States, with a focus on medical devices for cardiovascular conditions including coronary artery disease, congestive heart failure, and peripheral arterial disease. The CrossPoint TransAccess Catheter System, featuring phased array intravascular ultrasound imaging and a proprietary needle delivery mechanism, has been developed for targeted cell delivery to regenerate damaged heart tissue. FDA 510(k) clearance was obtained in 2002.
Transvascular's top competitors include Silk Road Medical, Lifetech Scientific Corporation and InterShunt Technologies.
Transvascular has 5 investors. Key investors include Medtronic, Bessemer Venture Partners, NEA, Johnson & Johnson Innovation – JJDC, and Three Arch Partners.